Last reviewed · How we verify
Atazanavir ritonavir
Atazanavir is a protease inhibitor that blocks HIV protease, preventing viral polyprotein cleavage and maturation; ritonavir is a booster that inhibits cytochrome P450 metabolism to increase atazanavir levels.
Atazanavir ritonavir is a combination antiretroviral therapy used for treating HIV. It has shown efficacy in multiple clinical trials, including pediatric populations. The drug is well-tolerated but has specific safety considerations, particularly in pregnant women and those with renal impairment.
At a glance
| Generic name | Atazanavir ritonavir |
|---|---|
| Sponsor | Göteborg University |
| Drug class | HIV protease inhibitor |
| Target | HIV protease |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Atazanavir binds to and inhibits HIV protease, an enzyme essential for processing viral precursor proteins into functional components required for infectious particle assembly. Ritonavir, a potent CYP3A4 inhibitor, is co-administered at low dose to dramatically increase atazanavir plasma concentrations and half-life, allowing for once-daily dosing and improved efficacy. Together, they suppress HIV replication by preventing the formation of mature, infectious viral particles.
Approved indications
- HIV-1 infection in treatment-naïve and treatment-experienced adults
- HIV-1 infection in combination antiretroviral therapy
Common side effects
- Hyperbilirubinemia
- Jaundice
- Nausea
- Diarrhea
- Headache
- Rash
- Nephrolithiasis
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Atazanavir ritonavir CI brief — competitive landscape report
- Atazanavir ritonavir updates RSS · CI watch RSS
- Göteborg University portfolio CI